Yuki Mukai1,2, Yumiko Minagawa2, Hiromi Inoue3, Akiko Sato4, Kengo Matsui2, Takanori Fukuda3, Kazuya Onuma3, Hideyuki Hongo2, Ryosuke Shirata2, Hironori Nagata2, Harumitu Hashimoto5, Tomio Inoue6, Masaharu Hata4, Motoko Omura2. 1. Department of Radiation Oncology, Yokohama City University Graduate School of Medicine, Yokohama, Japan y_mukai@yokohama-cu.ac.jp. 2. Department of Radiation Oncology, Shonan Kamakura General Hospital, Kamakura, Japan. 3. Department of Obstetrics and Gynecology, Shonan Kamakura General Hospital, Kamakura, Japan. 4. Department of Radiation Oncology, Yokohama City University Graduate School of Medicine, Yokohama, Japan. 5. Department of Radiation Oncology, Shonan Fujisawa Tokushukai Hospital, Fujisawa, Japan. 6. Department of Advanced Medical Center, Shonan Kamakura General Hospital, Kamakura, Japan.
Abstract
BACKGROUND/AIM: This study aimed to evaluate the clinical outcome of intensity-modulated radiation therapy (IMRT) and high-dose-rate intracavitary brachytherapy (HDR-ICBT) in uterine cervical cancer (UCC). IMRT consisted of whole-pelvic radiation therapy (WPRT) and sequential WPRT with central-shielding (WPRT-CS). PATIENTS AND METHODS: Thirty UCC patients treated with IMRT using TomoTherapy, were retrospectively analyzed. RESULTS: The median dose of WPRT and WPRT-CS was 36 and 14.4 Gy and the median total dose of these was 50 Gy in 25 fractions (Fr). Median HDR-ICBT dose/Fr to Point A was 25 Gy/5 Fr. Median 2 Gy per fraction-equivalent dose (EQD2) of combined WPRT and HDR-ICBT to Point A (α/β=10) was 71.0 Gy. The 3-year local control, disease-free survival, and overall survival rates were 89.9%, 83.3%, and 86.3%. CONCLUSION: IMRT of WPRT and WPRT-CS given in combination with HDR-ICBT was a feasible therapy resulting in good disease control and tolerance in patients with UCC. Copyright
BACKGROUND/AIM: This study aimed to evaluate the clinical outcome of intensity-modulated radiation therapy (IMRT) and high-dose-rate intracavitary brachytherapy (HDR-ICBT) in uterine cervical cancer (UCC). IMRT consisted of whole-pelvic radiation therapy (WPRT) and sequential WPRT with central-shielding (WPRT-CS). PATIENTS AND METHODS: Thirty UCC patients treated with IMRT using TomoTherapy, were retrospectively analyzed. RESULTS: The median dose of WPRT and WPRT-CS was 36 and 14.4 Gy and the median total dose of these was 50 Gy in 25 fractions (Fr). Median HDR-ICBT dose/Fr to Point A was 25 Gy/5 Fr. Median 2 Gy per fraction-equivalent dose (EQD2) of combined WPRT and HDR-ICBT to Point A (α/β=10) was 71.0 Gy. The 3-year local control, disease-free survival, and overall survival rates were 89.9%, 83.3%, and 86.3%. CONCLUSION: IMRT of WPRT and WPRT-CS given in combination with HDR-ICBT was a feasible therapy resulting in good disease control and tolerance in patients with UCC. Copyright
Authors: Sabrina T Heijkoop; Thomas R Langerak; Sandra Quint; Jan Willem M Mens; Andras G Zolnay; Ben J M Heijmen; Mischa S Hoogeman Journal: Radiother Oncol Date: 2015-09-22 Impact factor: 6.280